English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 13 December 2016, 15:41 JST
Share:
    

Source: Hitachi, Ltd.
Agreement Regarding Cooperation on Development of Fifth-Generation Quantum Beam Cancer Treatment Facility (Quantum Scalpel)
Signed by QST, Sumitomo Heavy Industries, Toshiba, Hitachi, and Mitsubishi Electric

TOKYO, Dec 13, 2016 - (JCN Newswire) - Today, the National Institutes for Quantum and Radiological Science and Technology (QST), Sumitomo Heavy Industries, Ltd., Toshiba Corporation, Hitachi, Ltd., and Mitsubishi Electric Corporation signed an "Agreement on Comprehensive Cooperation on Fifth-Generation Quantum Beam Cancer Treatment Facility".

QST successfully developed the world's first heavy ion beam treatment facility for treating cancer in 1994 and has built a track record of treating over 10,000 people up until now. In the course of this, QST has drawn up a vision to establish heavy ion therapy, which imposes fewer burden on patient than surgery and other cancer treatment methods, and does not cause immunosuppression, as the basic method of treating cancer in the future. QST intends to achieve its goal of zero cancer deaths by widely spreading and enhancing the adoption of this promising method.

For that reason, QST plans to develop a fifth-generation quantum beam cancer treatment facility (Quantum Scalpel) that can be used and operated at every potential medical institution in Japan and abroad. To be specific, it will develop a heavy ion cancer treatment facility using laser acceleration technology, superconducting technology, and other technology to achieve dramatic reductions in size and construction costs. In parallel with those efforts, it will promote performance improvements, such as demonstrations of practicality, for multi-ion beams, which promises to be more effective at treating cancer than current heavy ion treatment facilities, which use carbon ions.

The four companies Sumitomo Heavy Industries, Toshiba, Hitachi, and Mitsubishi Electric, each of which possesses its own characteristic advanced technical expertise and constantly developing capabilities needed to achieve the assumed tasks of this cooperative endeavor, today agreed to the plan to develop this fifth-generation quantum beam cancer treatment facility and have signed a "Agreement on Comprehensive Cooperation on Fifth-Generation Quantum Beam Cancer Treatment Facility" with QST.

Based on the signing of this agreement, QST, Sumitomo Heavy Industries, Toshiba, Hitachi, and Mitsubishi Electric will apply their respective R &D capabilities, human resources, equipment, and facilities to the performance of activities in accordance with the division of roles to be agreed upon in future deliberations, with the aim of quickly developing the fifth-generation quantum beam cancer treatment facility (Quantum Scalpel).

Contact:
Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111



Topic: Press release summary
Source: Hitachi, Ltd.

Sectors: Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
Hitachi, Ltd. Links

http://www.hitachi.com

https://www.facebook.com/hitachi.global/

https://twitter.com/hitachiglobal?lang=en

https://www.youtube.com/user/HitachiBrandChannel

https://ph.linkedin.com/company/hitachi

Hitachi, Ltd. Related News
Friday, 5 April 2024, 17:15 JST
Hitachi Energy and SP Energy Networks to boost renewable energy flow
Friday, 5 April 2024, 17:00 JST
Hitachi Selected as "Excellent TCFD Disclosure" by GPIF's External Asset Managers for the Third Consecutive Year
Tuesday, 26 March 2024, 19:04 JST
JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry
Friday, 22 March 2024, 16:04 JST
Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year
Tuesday, 19 March 2024, 19:11 JST
Hitachi Collaborates with NVIDIA to Accelerate Digital Transformation with Generative AI
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575